Aslan Pharmaceuticals Limited's Comment on Supply Chain
The company sources raw materials for its product candidates through contract manufacturers and other third-party manufacturers, without direct control over the acquisition process or timing. Delays in supply, particularly when replacing manufacturers, may significantly impact clinical trials, product testing, regulatory approval, and commercial launch timelines. The company has not established long-term commercial supply agreements with current or alternative manufacturers but plans to do so prior to any commercial launch contingent on U.S. FDA approval. Failure to secure such agreements on reasonable terms or in a timely manner could materially affect the business and product launch. Manufacturing scale-up may present challenges, including potential impurities that could lead to increased regulatory scrutiny, costs, and delays. The company anticipates continued reliance on third-party manufacturers, with increased demands if product candidates receive approval and are commercialized.
Aslan Pharmaceuticals Limited's Comment on Supply Chain
The company sources raw materials for its product candidates through contract manufacturers and other third-party manufacturers, without direct control over the acquisition process or timing. Delays in supply, particularly when replacing manufacturers, may significantly impact clinical trials, product testing, regulatory approval, and commercial launch timelines. The company has not established long-term commercial supply agreements with current or alternative manufacturers but plans to do so prior to any commercial launch contingent on U.S. FDA approval. Failure to secure such agreements on reasonable terms or in a timely manner could materially affect the business and product launch. Manufacturing scale-up may present challenges, including potential impurities that could lead to increased regulatory scrutiny, costs, and delays. The company anticipates continued reliance on third-party manufacturers, with increased demands if product candidates receive approval and are commercialized.
Sources:
Aslan Pharmaceuticals Limited's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Aslan Pharmaceuticals Limited’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
